Project Title: Characterisation of novel anti-glycan mAbs
targeting pancreatic cancer
Project Aims: To progress the team’s work in harnessing certain types of sugars found only on the surface of tumours and engineering antibodies that bind to them, stimulating an immune response against the tumour. To date, Professor Durrant and her team have engineered five novel antibodies that are specific to pancreatic cancer types and hopes to create two more. PCRF funding will also allow the team to test their effectiveness in killing tumours in animal models, before genetically engineering them to work with human pancreatic cancer.